Trial Profile
A study evaluating effect of primary and secondary immunodeficiency disorders on pharmacokinetics of intravenous Immunoglobulin G (Privigen®).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2017
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Pharmacokinetics
- 22 Mar 2017 New trial record
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology